ReviewImmunological reviews2016
Engineered hapten-binding antibody derivatives for modulation of pharmacokinetic properties of small molecules and targeted payload delivery.
Review in Immunological reviews, 2016. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 9 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
9 citing papers in PubMed.
- Molecular basis for antibody recognition of multiple drug-peptide/MHC complexes.Proceedings of the National Academy of Sciences of the United States of America · 2024Article
- Nasal Nanovaccines for SARS-CoV-2 to Address COVID-19.Vaccines · 2022Review
- Immunosensor of Nitrofuran Antibiotics and Their Metabolites in Animal-Derived Foods: A Review.Frontiers in chemistry · 2022Review
- Format chain exchange (FORCE) for high-throughput generation of bispecific antibodies in combinatorial binder-format matrices.Nature communications · 2020Article
- Antibody-targeted chromatin enables effective intracellular delivery and functionality of CRISPR/Cas9 expression plasmids.Nucleic acids research · 2019Article
- Structural basis for chemically-induced homodimerization of a single domain antibody.Scientific reports · 2019Article
- MicroRNA-Directed Neuronal Reprogramming as a Therapeutic Strategy for Neurological Diseases.Molecular neurobiology · 2018Review
- Bispecific Antibodies as a Development Platform for New Concepts and Treatment Strategies.International journal of molecular sciences · 2016Review
- Human Serum Albumin Domain I Fusion Protein for Antibody Conjugation.Bioconjugate chemistry · 2016Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Hapten-binding antibodies have for more than 50 years played a pivotal role in immunology, paving the way to antibody generation (as haptens are very important and robust immunogens), to antibody characterization (as the first structures generated more than 40 years ago were those of hapten binders), and enabled and expanded antibody engineering technologies. The latter field of engineered antibodies evolved over many years and many steps resulting in recombinant humanized or human-derived antibody derivatives in multiple formats. Today, hapten-binding antibodies are applied not only as reagents and tools (where they still play an important part) but evolved also to engineered targeting and pretargeting vehicles for disease diagnosis and therapy. Here we describe recent applications of hapten-binding antibodies and of engineered mono- and bispecific hapten-binding antibody derivatives. We have designed and applied these molecules for the modulation of the pharmacokinetic properties of small compounds or peptides. They are also integrated as additional binding entities into bispecific antibody formats. Here they serve as non-covalent or covalent coupling modules to haptenylated compounds, to enable targeted payload delivery to disease tissues or cells.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.